Table 4

Effect of TMP-SMX prophylaxis on 1-year PCP incidence and related mortality in the whole population (n=1522)

1-year PCP incidence1-year PCP-related mortality*
HR
(95% CI)
HR
(95% profile likelihood CI)
Univariable analysisMultivariable analysis†Univariable analysisMultivariable analysis‡
TMP-SMX prophylaxis0.17 (0.02 to 1.22)0.06 (0.004 to 0.66)0.21 (0.002 to 1.61)0.09 (0.0007 to 0.76)
P value for HR0.0780.0220.1650.023
  • *Firth’s panelised maximum likelihood was used due to complete separation of outcome.

  • †Included age, MPA, initial steroid dose (≥60 mg/day prednisone vs not), concomitant cyclophosphamide pulse and baseline lymphopenia as covariates, and was also adjusted for clustering.

  • ‡Included age, GPA, MPA and concomitant steroid pulse as covariates, and was also adjusted for clustering.

  • GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; PCP, pneumocystis pneumonia; TMP-SMX, trimethoprim-sulfamethoxazole.